NeuroPace (NPCE) Deferred Taxes (2020 - 2021)
NeuroPace's (NPCE) quarterly Deferred Taxes came in at -$47000.0 in Q4 2021, down 122.27% year-on-year from $211000.0 in Q4 2020, and little changed quarter-over-quarter from -$47000.0 in Q3 2021.
NeuroPace (NPCE) Deferred Taxes (2020 - 2021) Analysis & Trends
NeuroPace's Deferred Taxes history runs 2 years deep, the most recent figure standing at -$47000.0 for Q4 2021.
- On a quarterly basis, Deferred Taxes fell 122.27% year-over-year to -$47000.0 in Q4 2021; TTM through Sep 2022 was -$47000.0, a 84.74% increase from a year earlier, with the FY2021 full-year figure at -$566000.0, down 4616.67% from the prior year.
- Deferred Taxes was little changed at -$47000.0 in Q4 2021 per NPCE's latest filing, from -$47000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $211000.0 in Q4 2020 and bottomed at -$294000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.32 Bn | 177.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | -33.00 Mn |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | -8.00 Mn |
| 4 | Boston Scientific | 68.65 Bn | 67.20 Bn | 3.61 Bn | -351.00 Mn |
| 5 | Edwards Lifesciences | 47.43 Bn | 43.76 Bn | 1.29 Bn | -9.40 Mn |
| 6 | GE HealthCare Technologies | 28.48 Bn | 26.19 Bn | 1.98 Bn | - |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | 7.30 Mn |
| 8 | Smith & Nephew | 26.98 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.54 Bn | 22.42 Bn | 2.07 Bn | 51.51 Mn |
| 10 | NeuroPace | 514.69 Mn | 460.71 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -47,000.00 |
| Sep 30, 2021 | -47,000.00 |
| Jun 30, 2021 | -294,000.00 |
| Mar 31, 2021 | -178,000.00 |
| Dec 31, 2020 | 211,000.00 |
| Sep 30, 2020 | -44,000.00 |
| Jun 30, 2020 | -105,000.00 |
| Mar 31, 2020 | -74,000.00 |